EPO and obesity due to melanocortin 4 receptor deficiency: By increasing EPO levels, ROX may be used in treating obesity caused by high lipid intake, taking into account that the equilibrium between osteogenesis and adipogenesis is managed via EPO/EPOR signaling during the inflammation process caused by obesity [17].